Diabetes Drug Benefits MS Patients In Small Clinical Trial.

reports that diabetes drug Actos (pioglitazone) “benefited multiple sclerosis patients with metabolic syndrome in a small trial.” In the study of 50 MS patients with obesity, “those receiving the active drugs showed reductions in several biomarker measures including MRI lesion burden compared with the untreated controls, according to a report published on Monday in JAMA Neurology.” http://www.medpagetoday.com/Endocrinology/MetabolicSyndrome/56607